Navigation Links
Watson Confirms Amphastar Patent Lawsuit
Date:9/22/2011

PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts.  The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Momenta's U.S. Patent Nos. 7,790,466 and 7,575,886.  Enoxaparin Sodium Injection is a generic equivalent to Sanofi-aventis' LOVENOX®.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Watson and Amphastar intend to vigorously defend the claims in the lawsuit.  Pursuant to terms of the distribution agreement between Watson and Amphastar, Watson believes it will be fully indemnified by Amphastar for all costs, expenses and damages, if any, incurred in connection with the lawsuit.About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products. Amphastar's s
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical ... CCM ), a leading specialty hospital management ... radiotherapy and diagnostic imaging centers in China ... its Board of Directors declared a special cash dividend ... Depositary Share ("ADS")) on the Company,s outstanding ordinary shares. ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2
... , WASHINGTON, Dec. 11 Nabe News ... medicines are in development to fight diabetes. The report details a ... clinical trials and awaiting approval by the U.S. Food and Drug Administration. ... ( PhRMA ). , Diabetics do not produce or properly use ...
... R.I., Dec. 11 CVS Caremark (NYSE: CVS ... Vice President and Chief Human Resources Officer, effective January 1, ... his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , ... has more than 30 years of human resources experience. ...
Cached Medicine Technology:183 New Medicines in Development for Diabetes 2CVS Caremark Names New Chief Human Resources Officer 2
(Date:7/28/2014)... 28, 2014 A lush green lawn offers ... the summer. However, the summer heat, lack of rain, foot ... brown, weak and unhealthy. The Grounds Guys recommends these suggestions ... a lawn once a week and set the height on ... protects the grass roots from heat and allows roots to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Quincy Bioscience, ... , is pleased to announce the release of the ... company president and co-founder Mark Underwood. , The Brain ... information, offering useful techniques for readers to improve memory ... an unavoidable conclusion, The Brain Health Guide provides ways ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... -- Elementary school students seem to be satisfied with the ... new study of school officials. , , New meal standards ... into effect in the fall of 2012. At the time, ... throw away most of their food. But the new study ... case. , , "The updated meals standards are resulting in ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Healthy School Lunches Get Thumbs Up From Students 2
... Infuser, a,medical device used extensively in Combat Support Hospitals to treat ... to,save the life of an Omaha, NE Police Officer. , ... during a traffic stop. One of the bullets,hit him in the ... "Injury to this area is ...
... don,t respond at first not helped by maintenance treatment, ... Maintenance therapy using low-dose peginterferon doesn,t help patients with ... initial round of treatment, new research suggests. , The ... with liver disease over the course of four years. ...
... can outperform animal and human derived serum in CHO cell culture. ... ... -- Cellastim has proven to be a robust replacement for serum ... kinetics and productivity of CHO cell lines across a variety of ...
... statement by Betsy Ryan, President and CEO, New Jersey Hospital ... today announced that six New Jersey hospitals will share funding ... news for those facilities, but the more sobering headline is ... away. While a worthy effort, clearly the needs of New ...
... Calif., Dec. 3 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... Board of Directors to resign as,the Chief Executive Officer ... board has named Matthew T. Plavan, the Company,s Executive,Vice ...
... Dec. 3 The makers of TYLENOL(r) Warming,Liquids have embarked ... so they can warm up. Already a success in New ... complimentary,transportation within the city limits. , ... the city limits of the,District of Columbia, with a maximum ...
Cached Medicine News:Health News:Belmont(R) Rapid Infuser Helps Save Officer's Life 2Health News:Hepatitis C Therapy Useless for Some 2Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 3Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 4Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 5Health News:The Makers of TYLENOL(R) Warming Liquids Offer Free 'Warming' Taxi Rides in Washington, D.C. 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: